MTIM
TSHA icon

Marathon Trading Investment Management’s Taysha Gene Therapies TSHA Stock Holding History

Marathon Trading Investment Management’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-45,340
Closed -$102K – 343
2024
Q2 		$102K Sell
45,340
-178,560
-80% -$520K 0.01% 213
2024
Q1 		$643K Buy
+223,900
New +$467K 0.05% 138

Other funds holding TSHA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Avoro Capital Advisors
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Marathon Trading Investment Management's TSHA Position: Q3 2024 in Review

Marathon Trading Investment Management sold out of Taysha Gene Therapies (TSHA) in Q3 2024, closing a stake of 45,340 shares — an estimated $102K sold.

Marathon Trading Investment Management first reported a position in TSHA in Q1 2024 and held it in 2 quarters. The position peaked at $643K in Q1 2024. 119 funds tracked by Wall St. Rank hold TSHA as of Q3 2024.

  • Marathon Trading Investment Management reported no remaining Taysha Gene Therapies position as of Q3 2024 after selling out during the quarter.
  • Marathon Trading Investment Management sold 45,340 Taysha Gene Therapies shares in Q3 2024, an estimated $102K.
  • Marathon Trading Investment Management first reported a position in Taysha Gene Therapies in Q1 2024 and held it in 2 quarters.
  • Marathon Trading Investment Management's Taysha Gene Therapies position peaked at $643K in Q1 2024.
  • 119 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q3 2024.

Based on Marathon Trading Investment Management's 13F filing for Q3 2024, filed 7 Nov 2024.